Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn ...
The first clinical trial of an antiviral drug's effectiveness in people exposed to the deadly Ebola strain spreading in the ...
The Manila Times on MSN
Trial of potential Ebola antiviral under way — WHO
GENEVA, Switzerland — The first clinical trial is under way of an antiviral drug's effectiveness in people exposed to the ...
GlobalData on MSN
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
The interim analysis included 426 participants aged one year and above.
MedPage Today on MSN
Aspirin Alone Gets the Job Done for Clot Prevention After Joint Surgery
Regimens may drop the direct anticoagulants for some patients, based on EPCAT III ...
Wilate is now approved for routine prophylaxis across all patient ages and forms of von Willebrand disease. Trial results ...
PEP, aims to assess the effectiveness of the antiviral obeldesivir in post-exposure prophylaxis, for people who have been in ...
GENEVA, Switzerland - The first clinical trial is underway of an antiviral drug's effectiveness in people exposed to the ...
Label expansion establishes the therapy as the first VWF concentrate indicated for routine prophylaxis across all age groups ...
The World Health Organization launched the first clinical trial on Tuesday to test whether an antiviral drug can prevent ...
Octapharma USA announced that pediatric patients, including children younger than 6 years of age, with von Willebrand Disease (VWD) now have access to routine prophylaxis to help reduce the frequency ...
Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results